Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Diagnosis and management of myeloma in the very elderly patient is challenging. Treatment options have vastly improved for elderly myeloma patients but still require the clinician to personalize therapy. In this paper, we offer evidence-based, pragmatic advice on how to overcome six of the main challenges likely to arise: 1) diagnosis of myeloma in this age group, 2) assessment of the need for treatment, and the fitness for combination chemotherapy, 3) provision of the best quality of supportive care, 4) choice of combination chemotherapy in those fit enough for it, 5) treatment of relapsed myeloma, and 6) provision of end of life care. With an increased burden of comorbidities and a reduced resilience to treatment and its associated toxicities, the management of myeloma in this age group requires a different approach to that in younger patients to maximize both quality and length of life.

Original publication

DOI

10.2147/CIA.S89465

Type

Journal article

Journal

Clin Interv Aging

Publication Date

2016

Volume

11

Pages

423 - 435

Keywords

diagnosis, elderly, myeloma, treatment, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Comorbidity, Evidence-Based Medicine, Frail Elderly, Humans, Multiple Myeloma, Randomized Controlled Trials as Topic, Terminal Care